Have you evaluated the performance of Eli Lilly's (LLY) international operations during the quarter that concluded in September 2025? Considering the extensive worldwide presence of this drugmaker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.
In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importance on grasping the extent of a company's dependence on international markets, as it sheds light on the firm's earnings stability, its skill in leveraging various economic cycles and its broad growth potential.
Participation in global economies acts as a defense against economic difficulties at home and a pathway to more rapidly developing economies. However, it also comes with the complexities of dealing with fluctuating currencies, geopolitical risks and different market dynamics.
Upon examining LLY's recent quarterly performance, we noticed several interesting patterns in the revenue generated from its international segments, which are commonly analyzed and observed by Wall Street experts.
The recent quarter saw the company's total revenue reaching $17.6 billion, marking an improvement of 53.9% from the prior-year quarter. Next, we'll examine the breakdown of LLY's revenue from abroad to comprehend the significance of its international presence.
A Closer Look at LLY's Revenue Streams Abroad
Of the total revenue, $555 million came from Japan during the last fiscal quarter, accounting for 3.2%. This represented a surprise of +2.2% as analysts had expected the region to contribute $543.06 million to the total revenue. In comparison, the region contributed $521 million, or 3.4%, and $429.1 million, or 3.8%, to total revenue in the previous and year-ago quarters, respectively.
During the quarter, Other foreign countries contributed $1.69 billion in revenue, making up 9.6% of the total revenue. When compared to the consensus estimate of $1.25 billion, this meant a surprise of +35.43%. Looking back, Other foreign countries contributed $1.18 billion, or 7.6%, in the previous quarter, and $1.11 billion, or 9.7%, in the same quarter of the previous year.
Europe accounted for 19.9% of the company's total revenue during the quarter, translating to $3.5 billion. Revenues from this region represented a surprise of +37.25%, with Wall Street analysts collectively expecting $2.55 billion. When compared to the preceding quarter and the same quarter in the previous year, Europe contributed $2.57 billion (16.6%) and $1.63 billion (14.2%) to the total revenue, respectively.
Revenue Forecasts for the International Markets
For the current fiscal quarter, it is anticipated by Wall Street analysts that Lilly will post revenues of $17.57 billion, which reflects an increase of 29.8% the same quarter in the previous year. The revenue contributions are expected to be 3.4% from Japan ($599.46 million), 7.6% from Other foreign countries ($1.33 billion) and 16.8% from Europe ($2.96 billion).
For the full year, the company is expected to generate $63.91 billion in total revenue, up 41.9% from the previous year. Revenues from Japan, Other foreign countries and Europe are expected to constitute 3.2% ($2.07 billion), 7.4% ($4.76 billion) and 16.4% ($10.47 billion) of the total, respectively.
The Bottom Line
The dependency of Lilly on global markets for its revenues presents a mix of potential gains and hazards. Thus, monitoring the trends in its overseas revenues can be a key indicator for predicting the firm's future performance.
In an era of growing international ties and escalating geopolitical disputes, financial analysts on Wall Street pay keen attention to these developments to fine-tune their earnings estimations for businesses operating across borders. It's important to note, however, that a range of additional variables, like a company's local market status, also play a crucial role in shaping these forecasts.
At Zacks, a company's changing earnings outlook is given considerable attention due to its proven, strong influence on a stock's price performance in the near term. The connection here is straightforward and positive: when earnings estimates are revised upward, the stock price generally follows suit, increasing as well.
Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.
At the moment, Lilly has a Zacks Rank #3 (Hold), signifying that its performance may align with the overall market trend in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Examining the Latest Trends in Eli Lilly's Stock Value
Over the past month, the stock has gained 6.1% versus the Zacks S&P 500 composite's 2.1% increase. The Zacks Medical sector, of which Lilly is a part, has declined 0.9% over the same period. The company's shares have increased 41.1% over the past three months compared to the S&P 500's 10.3% increase. Over the same period, the sector has risen 8.7%
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Eli Lilly and Company (LLY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
